Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Selenium-75-labeled sucralfate: comparison with other radiolabels and initial clinical studies

Journal Article · · Am. J. Physiol. Imag.; (United States)
OSTI ID:6827561

Sucralfate was synthesized to include a /sup 75/Se label, then compared with /sup 111/In-sucralfate and /sup 99m/Tc-Human serum albumin (HSA)-sucralfate in vitro and in an animal ulcer model. The /sup 75/Se label was the only one of the three that was stable in both human gastric juice and simulated intestinal fluid in vitro. In rats with gastric ulcers, ulcer:nonulcer ratios of bound radioactivity averaged 15.4, 6.3, and 5.6 for /sup 75/Se, /sup 111/In, and /sup 99m/Tc-HSA labels, respectively. Biodistribution studies of /sup 75/Se-sucralfate indicated that little is absorbed from the gastrointestinal tract, and the distribution is similar to that of /sup 14/C-sucralfate. Selective binding of /sup 75/Se sucralfate was successfully imaged in patients with esophagitis (esophageal mean T1/2 binding = 65 +/- 32 min), gastritis (gastric mean T 1/2 binding = 118 +/- 34 min), and gastric ulcers (ulcer mean T 1/2 binding = 135 +/- 59 min). Duodenal ulcers were not successfully imaged. Normal subjects showed no abnormal localization of sucralfate, and esophageal and gastric clearances were rapid.

Research Organization:
Temple Univ. Hospital, Philadelphia, PA (USA)
OSTI ID:
6827561
Journal Information:
Am. J. Physiol. Imag.; (United States), Journal Name: Am. J. Physiol. Imag.; (United States) Vol. 3:1; ISSN AJPIE
Country of Publication:
United States
Language:
English